Testing an epigenetic drug for advanced solid tumors
Part of Cancer clinical trials.
This early-phase study tests Aza-TdC in adults with advanced solid cancers that have grown despite standard treatment, or for which no standard options exist. The goal is to see if the drug can be given safely and start to show signs of benefit against tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have a solid tumor cancer that has progressed on standard treatment, or there is no standard treatment available.
- Your overall health is good enough for study treatment (ECOG 0 to 2).
- Your blood counts and organ function are in acceptable ranges (for example, enough white blood cells and platelets, and adequate liver and kidney function).
- You must be able to take pills, understand the study, and sign consent, and be willing to give blood and urine for research.
- Because the drug can harm a pregnancy, you must use two reliable birth-control methods during the study and for 3 months after the last dose (and you cannot be pregnant or breastfeeding).
- Your heart pumping strength must be okay (left ventricular ejection fraction >45% by scan).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests how safe a new drug (ABSK-021) is, what side effects it causes, and how the body processes it in people with advanced solid tumors. You may be eligible if your cancer has grown despite standard treatments or if no standard treatment exists.
This Phase 1/2 study tests AZD9574 alone or with other cancer treatments in people with advanced solid tumors. It focuses on cancers with specific DNA repair gene changes (like BRCA1/2) or other matching tumor features, and aims to see if the treatment can shrink tumors and improve outcomes.
This trial tests a new drug called ZE94-0605 for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if it is safe and can shrink tumors.
This study tests how a new experimental drug called AZD1390 moves through and is processed by your body. Researchers use a specially labeled version of the drug to track this process, which may help them understand how to use it safely in future cancer patients.
This Phase 1 study tests DCSZ11 in people with advanced or metastatic solid tumors (cancers that can’t be removed or have spread) given alone or with other treatments. It’s designed to find a safe dose and to see whether the treatment shows signs of shrinking cancer.
This Phase I/II trial tests an investigational treatment in people with advanced solid tumors that have grown despite standard therapy, or where standard options aren’t available. In later Phase II, the trial mainly enrolls patients whose tumor shows a specific DNA repair problem (DDR defect).
Hear when a new Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.